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 Introduction 
Older age, unfavorable cytogenetics, and FLT3-ITD mutation are adverse prognostic 
indicators in acute myeloid leukemia (AML) placing the disease under poor-risk category 
[1-5]. Complex biologic factors in poor-risk AML confer resistance to chemotherapy [6-9]. 
Incorporation of novel non-chemotherapeutic targeted agents into the treatment of poor-
risk AML is therefore on demand.  Subject of such approaches may include epigenetic 
pathways that affect tumor suppressor genes. Apoptosis in leukemic blasts can be promoted 
through upregulation of tumor suppressors DAPK1, RUNX3, and p16INK4A/CDKN2A 
[10,11]. We previously identified an oncogenic pathway in AML repressing promoter of 
DAPK1 gene through an interaction of p52NF-κB and histone deacetylases [12].  
Furthermore, leukemia stem cell promotion occurs in epigenetically repressed FLT3-ITD 
positive (+ve) or complex cytogenetics disease [13]. Indeed, a cause for suboptimal 
response to single-agent FLT3 inhibitors may be an epigenetic collaboration in the 
pathogenesis of FLT3-ITD-mediated AML [14,15].  
 
We hypothesized that epigenetic de-repression of specific tumor suppressor genes in 
addition to inhibition of kinase-dependent proliferation systems can promote clinical anti-
leukemic effect in AML. We therefore designed sequential clinical trials to explore the safety 
and efficacy of epigenetic modification along with targeting selected cell proliferation 
pathways in poor-risk AML. The first trial combined FLT3/RAF inhibitor sorafenib and 
histone deacetylase inhibitor vorinostat in a phase 1 setting. The second trial tested 
addition of bortezomib to the previous combination for further tumor suppressor de-
repression through inhibition of p52NF-κB. Our findings on the molecular attributes of 
these studies have been reported separately [16]. This report describes clinical aspects of 
the two consecutive trials. 
 
Patient selection  
Both studies were approved by Indiana University School of Medicine Institutional Review 
Board. Sor/vor study included adult patients with a diagnosis of relapsed and/or refractory 
AML or older than 70 with previously untreated disease. Any cytogenetic or molecular 
profile was acceptable. The sor/vor/bor study enrolled only relapsed and/or refractory 
AML with FLT3-ITD+ve profile and/or poor-risk cytogenetics including -5, -7, or complex 
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 karyotype. Such selection was due to observation of response in patients with poor-risk 
cytogenetics or FLT3-ITD+ve disease in sor/vor trial.  
 
 
Trial Design and Treatment  
The sor/vor trial followed a 3+3 dose-escalation schedule in a phase I setting. Sorafenib was 
given orally at a dose of 400 mg twice daily, and oral vorinostat was given with dose 
escalation in successive cohorts. Each cycle of 21 days consisted of treatment for 14 days 
followed by 7 days of break. An interrupted schedule was chosen to avoid excessive 
myelosuppression. Patients who achieved at least 50% reduction of bone marrow blasts 
with the first cycle, were eligible to receive the second cycle. At least 10% reduction of bone 
marrow blasts, but not a complete remission with the second cycle, would make patients 
eligible for the third cycle. A maximum of 3 treatment cycles was planned. No further 
treatment would be given beyond a complete remission (CR).   
 
Sor/vor/bor was a phase I/II study with a 3+3 dose-escalation schedule in the phase I part.  
Vorinostat was given orally at 200 mg twice daily, initially in an interrupted fashion only on 
days 1-4 and 8-12, and later continuously. Oral sorafenib and intravenous bortezomib were 
given with dose escalation in successive cohorts. Each cycle consisted of 14 days of 
treatment followed by 7 days of break, 21 days total. Patients with continued response 
would continue on study. Up to 2 more cycles could be given beyond a CR. The phase II part 
of the study followed the same schedule of phase I, given at safe dose determined by the 
phase I part.   
 
Response was assessed by the guidelines reported by Cheson [17], and dose-limiting 
toxicity (DLT) was defined as any grade 3 or 4 non-hematologic toxicity.  
 
 
Results 
First trial (sor/vor study) 
Toxicity and optimal dose. Patient characteristics are summarized in table 1. A total of 15 
patients were enrolled, and 13 completed at least one cycle of therapy. Median age was 61 
years (37-74), with 8 males and 5 females. Two patients were in their 3rd relapse, one had 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 relapsed after allo-transplant, one older patient had previously untreated disease, and rest 
of patients were refractory to chemotherapy. One patient had grade 1 hand-foot syndrome, 
and another grade 2 nausea. One/six patient in the third (last) cohort developed grade 4 
diarrhea in the setting of neutropenic fever. The safe dose was determined as sorafenib 400 
mg and vorinostat 200 mg both twice daily for 14 days, followed by 7 days of rest. To 
further assess the safety and response, three more patients were enrolled into the study at 
the established optimal dose.  
 
Response. With the first cycle of treatment, seven/sixteen (44%) patients demonstrated a 
partial remission (PR) and 1/16 (6%) achieved a complete remission (CR) and remained 
disease-free for 5 months. Four partial responders received 1-2 more cycles with initial 
response but experienced disease progression.  Three partial responders to the first cycle 
did not receive a second cycle, one per personal preference and two due to increasing 
circulating blasts. The patient with CR carried a complex cytogenetics including 
monosomies 5 and 7.  
 
Second trial (sor/vor/bor study) 
Toxicity and optimal dose. Seventeen patients were enrolled in the phase I part (table 2). 
Fifteen patients completed at least one cycle of treatment. All patients had relapsed and/or 
refractory disease, and had received at least two lines of chemotherapy. Median age was 51 
years (24-73), with 10 males and 7 females. Most common toxicities were gastrointestinal 
disturbances (64.2%) including diarrhea, nausea, or vomiting reaching grade 2 in 14.2% of 
patients with no grade 3 or 4. Others included fatigue (31.3%), rash (21.4%), and 
neutropenic fever (7.1%); none greater than grade 2. The safe dose was sorafenib 400 mg 
and vorinostat 200 mg twice daily for 14 days, and bortezomib 1.3 mg/m2 IV on days 1, 4, 8, 
11, every 21 days.  
 
Response. In the phase I study 5 patients achieved CR with incomplete platelet recovery 
(CRi). Responses occurred across different cohorts. A total of 20 patients were enrolled into 
the phase II study. Majority of patients were heavily pretreated including stem cell 
transplantation in 5. Six patients were deemed unevaluable for response. Of 14 evaluable 
patients, 7 (50%) carried FLT3-ITD mutation and 7 (50%) had either complex cytogenetics 
or monosomy 7. One patient (7%) achieved CR, 1 (7%) CRi, and 2 patients (14%) 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 experienced a PR. Overall responses with all 37 patients in both phases, including 
unevaluable patients, were 1 CR (3%), 6 CRi (16%), and 2 PR (5%). All responders in both 
phases of the study carried FLT3-ITD mutation. Responders all experienced relapse within 
2 cycles of consolidation, and none was able to undergo transplant due to variety of reasons.  
 
 
Discussion 
The two consecutive studies were based on a hypothesis that epigenetic de-repression of 
tumor suppressor genes combined with inhibition of kinase-dependent proliferation 
systems can introduce a collaborative anti-leukemic effect. The first study demonstrated 
safety of combined kinase inhibitor sorafenib and epigenetic modulator vorinostat. In this 
study a clinical response, including 1 CR and 6 PR were observed in poor-risk AML.  
Analysis of bone marrow blasts in this study demonstrated up-regulation of tumor 
suppressors DAPK1, RUNX3, and CDKN2A along with reduction in FLT3-induced Id1 [16].  
 
The second trial established safety and assessed efficacy of sorafenib, vorinostat, and 
bortezomib combination. Bortezomib was added to further enhance de-repression of tumor 
suppressors through inhibition of p52NF-κB. In this study 1 CR (3), 6 CRi (16%), and 2 PR 
(5%) were observed. In this study also an upregulation of tumor suppressors of interest 
was noted in responders [16].   Maximum response in both studies occurred within the first 
2 cycles of treatment. The depth of response, as is evidenced by number of CR and CRi, was 
greater in the second study, reflecting potential role of proteasome inhibition in this 
combination.  Responses in both studies were distributed among different dose levels, 
suggesting sensitivity of leukemic cells to the combination regardless of clinical dosing.  
 
Single-agent sorafenib has shown efficacy in AML when administered continuously, with 
median time to best response of 27 to 46 days [18,19]. Majority of responders in both of our 
studies achieved best response within the first 14 days of therapy. Indeed, intracellular 
molecular changes predictive of response were observed in the AML blasts obtained from 
patient marrows as early as 3-4 days following initiation of treatment [16].  The expedited 
response observed in our studies is logically attributable to addition of vorinostat and 
possibly bortezomib.  
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 Patients were not kept on treatment extensively due to limitations in drug availability, but 
all relapses in sor/vor/bor occurred during consolidations, indicating long-term treatment 
would not be beneficial. The short duration of response to sorafenib in FLT3-ITD+ve disease 
is attributed to emergence of D835 tyrosine kinase domain mutation [18].  Additional 
epigenetic modulation in our studies did not improve such response duration.  
 
The two studies demonstrated safety of combination of sorafenib, vorinostat, and 
bortezomib at full approved doses in AML. These studies also showed potential for response 
to novel targeted-only therapies in poor-risk AML. These studies offer a platform towards 
further development of such rational combinations for the treatment of AML.  
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 Table 1. Sor/vor study patient characteristics 
Cohort Patient Age/Sex AML status Cytogenetics FLT3-ITD Response 
 
1 
1 71/M 3rd rel Normal - No 
2 56/M Rel, post transplant Normal - No 
3 65/M Primary ref -7 - PR 
 
2 
4 72/M 3rd rel t(1;6) - No 
5 72/M Rel/ref t(18;21) + PR 
6 37/F Rel/ref Normal - No 
 
 
 
 
3 
7 58/M Rel/ref Normal + PR 
8 74/M Untreated -5, -7 - CR 
9 46/F Rel/ref Complex - No 
10 74/M Primary ref Complex - PR 
11 60/F Primary ref Normal - No 
12 70/F Untreated Normal - PR 
13 42/F Primary ref Normal + PR 
14 53/M 2nd rel Trisomy 8 - No 
15 67/M Rel/ref Normal - No 
16 70/F Rel/ref Normal - PR 
Rel: Relapsed; Ref: Refractory; PR: Partial remission; CR: Complete remission 
Dosing: Sorafenib 400 mg twice daily in all cohorts. Vorinostat 100 mg twice daily in cohort 1; 200 mg in AM and 100 mg in PM 
in cohort 2; 200 mg twice daily in cohort 3. Each cycle consisted of 14 days of treatment and 7 days of rest. 
 
 
Table 2. Sor/vor/bor study patient characteristics 
 
Phase 
1 
 
Patient 
 
Age/Sex 
 
AML status 
 
Cytogenetics 
 
FLT3-ITD 
 
Response 
Cohort 1 1 33/M Rel post transplant (-7) - Unevaluable 
2 67/M Rel/Ref post 
transplant 
(-7q) + Unevaluable 
3 64/F Ref Complex - No  
4 54/F Rel/ref Complex - No  
 
Cohort 2 
5 55/F Rel/ref Normal + CRi 
6 67/M Rel/ref Normal + CRi 
7 64/M Ref Normal + Initial response 
 
Cohort 3 
8 35/M Ref Unavailable + Unevaluable 
9 73/M Ref Complex - No  
10 51/M Rel Complex - No  
11 63/M Ref Complex - No  
 
Cohort 4 
12 46/F Ref 46,XX,t(2;8) + Initial response 
13 50/F Ref Normal + CRi 
14 37/M Rel post transplant Unavailable + CRi 
 
Cohort 5 
15 40/F Ref Unavailable + No 
16 46/M Ref (-7)/Complex - No 
17 24/F Rel post transplant 46,XX,t(12;15) + CRi 
       
 
 
Phase 
2 
7 
patients 
2 Females 
5 Males 
Age 41-72 
4 Rel/ref 
1 Ref 
2 Rel post transplant 
 
Normal 
 
+ 
1 CR 
1 CRi 
2 PR 
7 
patients 
3 Females 
4 Males 
Age 50-71 
5 Rel/ref 
2 Rel post transplant 
Complex 
(-5) or (-7) 
 
- 
 
No 
6 
patients 
4 Females 
2 Males 
Age 54-73 
3 Rel/ref 
3 Ref 
2 Normal 
3 Complex 
1 (-5)  
2 + 
4 - 
Unevaluable 
3 discontinued due to patient preference 
2 died due to neutropenic fever 
1 lost to followup 
 
Rel: Relapsed; Ref: Refractory; CRi: Complete remission with incomplete platelet recovery 
Dosing: Sorafenib 200 mg twice daily in cohort 1 and 400 mg twice daily in next cohorts. Vorinostat 200 mg twice daily on days 1-4 and 8-12 
in cohorts 1-4, and continuously in cohort 5. Bortezomib 1.0 mg/m2 on days 1,8 in cohorts 1 and 2; 1.3 mg/m2 on days 1,8 in cohort 3; and 1.3 
mg/m2 on days 1,4,8,11 in cohorts 4 and 5. Each cycle consisted of 14 days of treatment and 7 days of rest. 
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